GLP-1 Market Timeline 2025–2027
Every major GLP-1 event from 2025 through 2027 — FDA actions, Medicare policy, manufacturer deals, pipeline drug decisions, and patent expirations. Source-cited. Filter by entity.
18events tracked · Confirmed events marked with solid dots, expected events with outlined dots, projected events with dashed outlines.
2025
5 eventsFDA declares semaglutide shortage over
FDA removes semaglutide (Ozempic, Wegovy) from the drug shortage list, formally ending the 503A compounding window for bulk-identical preparations. Semaglutide compounders given 60-90 days to wind down.
FDA.gov→FDA resolves tirzepatide shortage
FDA removes tirzepatide (Mounjaro, Zepbound) from the shortage list. 503B outsourcing facilities must now follow essentials-copies rules; mass-market compounded tirzepatide effectively ends for most pharmacies.
FDA.gov→SURMOUNT-OSA: Zepbound reduces sleep apnea events by 50–60%
Phase 3 results published — tirzepatide reduces obstructive sleep apnea events substantially in adults with obesity. Expands the non-diabetic label case and strengthens comorbidity-based Medicare coverage arguments.
NEJM→CMS finalizes Medicare GLP-1 Bridge demonstration rule
CMS publishes final rule for the 2026 Medicare GLP-1 Bridge Program. $50/month flat copay for Wegovy and Zepbound for Medicare Part D beneficiaries meeting BMI and comorbidity criteria.
CMS.gov→Orforglipron Phase 3 ATTAIN-1 readout
Lilly publishes Phase 3 data on orforglipron — the first oral small-molecule GLP-1 not requiring food restrictions like Rybelsus. Weight loss ~14.7% at 72 weeks, positioning orforglipron for scale manufacturing.
Lilly investor release→2026
9 eventsOral Wegovy launches in the US
Novo Nordisk ships oral semaglutide at the obesity-approved dose to US pharmacies. 170,000 prescriptions filled in the first three weeks — establishes oral GLP-1 as a commercial category.
Novo Nordisk press release→FDA issues 30 warning letters to telehealth marketers
FDA enforcement sweep targets telehealth companies making deceptive GLP-1 claims, obscuring compounded sourcing, or bundling lab fees. Marks the start of sustained telehealth scrutiny.
FDA Warning Letters→Hims–Novo deal: Hims drops compounded semaglutide
Hims partners with Novo Nordisk to distribute branded Wegovy/Ozempic at preferred pricing. Hims ends compounded semaglutide marketing. Shifts the telehealth landscape toward brand-only programs at the top tier.
Reuters coverage→FDA approves Foundayo — oral tirzepatide
FDA approves Eli Lilly's Foundayo, the first-in-class oral tirzepatide at the obesity dose. Cash-pay list price $299/mo via LillyDirect, $149/mo with savings card. 94% LillyDirect fill rate in launch weeks.
Lilly press release→Orforglipron PDUFA deadline
FDA target action date for orforglipron NDA. First oral small-molecule GLP-1 not requiring the Rybelsus-style administration protocol. Positions Lilly to scale oral GLP-1 via conventional manufacturing.
FDA approvals→Medicare GLP-1 Bridge Program launches
$50/month flat copay for Wegovy and Zepbound through Medicare Part D for eligible beneficiaries. First federal obesity-medication coverage at scale. Estimated 3.4M beneficiaries eligible at launch.
CMS.gov→Retatrutide Phase 3 TRIUMPH readout expected
Lilly's triple agonist (GLP-1 + GIP + glucagon) Phase 3 readout. Phase 2 data showed up to 24.2% weight loss at 48 weeks — highest for any obesity drug to date. Sets the next pipeline ceiling.
ClinicalTrials.gov NCT05882877→SELECT 5-year cardiovascular outcomes
Long-term follow-up of semaglutide cardiovascular outcomes trial expected to report at a major cardiology meeting. Confirms (or walks back) the 20% MACE reduction seen in the initial 3-year report.
AHA / ACC scientific sessions→Compounded tirzepatide enforcement sunset
FDA's extended enforcement discretion window for 503A compounded tirzepatide expected to close. Remaining compounding pharmacies must fully transition to essentials-copies framework or exit tirzepatide.
2027
4 eventsRetatrutide FDA NDA submission expected
Lilly files New Drug Application for retatrutide. If approved, becomes highest-efficacy obesity medication available. PDUFA target ~12 months post-filing, suggesting late 2027 / early 2028 approval.
Medicare GLP-1 Bridge first-year outcomes data
CMS publishes Year 1 data on the Bridge demonstration. Prescription volume, beneficiary weight-loss outcomes, and budget impact. Critical input for FY2028 coverage expansion decisions.
Semaglutide patent expiration approaches (US)
Core semaglutide composition-of-matter patents begin expiring in key jurisdictions. Novo has secondary patents (formulation, dose) that delay generic entry, but market structure begins shifting.
Potential generic semaglutide launch window opens
First generic semaglutide filings eligible for launch depending on patent litigation outcomes. Likely initial markets: Canada, EU. US generic semaglutide commercial availability projected 2028–2031.
Frequently asked
When does the Medicare GLP-1 Bridge Program launch?
July 1, 2026. The Medicare GLP-1 Bridge Program provides a $50/month flat copay for Wegovy and Zepbound to eligible Medicare Part D beneficiaries who meet BMI and comorbidity criteria.
Check your eligibility →When did the FDA end the semaglutide shortage?
January 2025.FDA removed semaglutide from the drug shortage list and gave compounding pharmacies a 60–90 day wind-down window. Tirzepatide followed in February 2025. This ended the era of widespread 503A-compounded GLP-1s.
What is Foundayo?
Foundayo is Eli Lilly's oral tirzepatide tablet, FDA approved in April 2026. It's the first oral tirzepatide at the obesity dose. Cash-pay list price is $299/month via LillyDirect, or $149/month with savings card.
What's next after Zepbound and Wegovy?
Retatrutide— Lilly's triple agonist (GLP-1 + GIP + glucagon) — is the most watched Phase 3 readout. Phase 2 showed up to 24.2% weight loss at 48 weeks. If approved (projected 2028), it resets the obesity-drug efficacy ceiling.
Make your decision on today's market
See our independent rankings of 40 GLP-1 providers, check your Medicare Bridge eligibility, or predict your weight loss based on clinical trial data.